spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ALIMTA 

 HSMN NewsFeed - 27 May 2022
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jul 2017
UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 15 Jun 2016
German Supreme Court Grants Lilly Appeal in Alimta(R) Vitamin Regimen Patent Lawsuit
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 28 Oct 2011
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Jun 2011
Endocyte Names Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2009
AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2009
ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2009
Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 May 2009
ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticasl Oncology Regulatory
 HSMN NewsFeed - 21 Oct 2008
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
Ireland Cancer Center and TRACON Pharmaceuticals Announce Treating the First Cancer Patient With TRC102, An Inhibitor of Chemotherapy Resistance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2007
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Oct 2007
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmacetuicals Oncology
 HSMN NewsFeed - 20 Sep 2007
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2007
Kylin Therapeutics Names Cancer Therapy Leader to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Talabostat Clinical Program Put on Clinical Hold by FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Mar 2007
Point Therapeutics Provides Clinical Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2006
EntreMed Commences Clinical Trial for MKC-1 in Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2006
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
ALIMTA
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.